Febuxostat
Treatment for Gout
Typical Dosage: 40 mg or 80 mg daily
Effectiveness
87%
Safety Score
65%
Clinical Trials
65
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
40 mg or 80 mg daily
Time to Effect
Days-weeks (sUA reduction), 6-12 months (flare reduction)
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$300
Side Effect Mgmt:$70
Total Annual:$670
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$770
Cost per Remission
$957
Comparison vs Allopurinol
Cost Difference
+$290/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Febuxostat Outcomes
for Gout
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+87%
Remission Rate
+70%
Common Side Effects
Nausea
+3%
Liver function abnormalities
+3%
Gout flares (initiation)
+8%
Cardiovascular events
+1%
Active Clinical Trials
2 active trials recruiting for Febuxostat in Gout
The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
NCT06622603NOT YET RECRUITINGPHASE4
59 participants
INTERVENTIONAL
Seongnam-si, South Korea
Started: Oct 15, 2024
Study on the Efficacy and Safety of Thermotherapy in the Treatment of Refractory Gout
NCT06653686NOT YET RECRUITINGNA
128 participants
INTERVENTIONAL
Started: Nov 1, 2024
Completed Clinical Trials
16 completed trials for Febuxostat in Gout
Long-Term Safety of Febuxostat in Subjects With Gout.
NCT00174941COMPLETEDPHASE2
116 participants
INTERVENTIONAL
Started: Mar 1, 2001
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
NCT00174967COMPLETEDPHASE2
153 participants
INTERVENTIONAL
Started: Jan 1, 2001
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
NCT00174915COMPLETEDPHASE3
1.07K participants
INTERVENTIONAL
Started: Feb 1, 2003
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
NCT00102440COMPLETEDPHASE3
760 participants
INTERVENTIONAL
Started: Jul 1, 2002
Efficacy and Safety of Oral Febuxostat in Participants With Gout
NCT00430248COMPLETEDPHASE3
2.27K participants
INTERVENTIONAL
Birmingham, United States +257 more
Started: Feb 1, 2007
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
NCT00175019COMPLETEDPHASE3
1.09K participants
INTERVENTIONAL
Started: Jul 1, 2003
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
NCT02139046COMPLETEDPHASE3
1.79K participants
INTERVENTIONAL
Binghamton, United States +191 more
Started: Apr 1, 2014
Phase III Trial of Febuxostat in Korea Gout Patients
NCT00821392COMPLETEDPHASE3
181 participants
INTERVENTIONAL
Started: Aug 1, 2006
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
NCT02082769COMPLETEDPHASE3
504 participants
INTERVENTIONAL
Started: Jul 1, 2011
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
NCT01654276COMPLETEDPHASE4
24 participants
INTERVENTIONAL
Dallas, United States
Started: May 1, 2012
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
NCT01736514COMPLETEDPHASE3
109 participants
INTERVENTIONAL
Kaohsiung City, Taiwan +3 more
Started: Mar 1, 2011
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
NCT05007392COMPLETEDPHASE3
451 participants
INTERVENTIONAL
Hefei, China +29 more
Started: Dec 21, 2021
Food Effect Study of Febuxostat XR in Healthy Participants
NCT02374164COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Austin, United States
Started: Feb 1, 2015
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
NCT00995618COMPLETEDPHASE2
24 participants
INTERVENTIONAL
Honolulu, United States +2 more
Started: Sep 1, 2009
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
NCT03131583COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Suzhou, China
Started: Feb 17, 2017
Lesinurad and Febuxostat Combination Extension Study in Gout
NCT01808144COMPLETEDPHASE3
196 participants
INTERVENTIONAL
Birmingham, United States +71 more
Started: Mar 1, 2013
Showing 20 of 66 total trials